ERBB2 and breast cancer: Altogether, our results indicate that cats presenting HER2-positive or TN normal-like tumors could benefit from immunostimulatory therapies (e.g., anti-PD-L1, anti-CTLA-4) and provide support to the use of spontaneous feline mammary carcinoma as a model for human breast cancer.